White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy - PubMed (original) (raw)
Review
. 2011 Apr 1;17(7):1664-73.
doi: 10.1158/1078-0432.CCR-10-2272. Epub 2011 Feb 15.
Affiliations
- PMID: 21325070
- DOI: 10.1158/1078-0432.CCR-10-2272
Review
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy
Jeffrey Weber et al. Clin Cancer Res. 2011.
Abstract
Adoptive T-cell therapy (ACT) using expanded autologous tumor-infiltrating lymphocytes (TIL) and tumor antigen-specific T cell expanded from peripheral blood are complex but powerful immunotherapies directed against metastatic melanoma. A number of nonrandomized clinical trials using TIL combined with high-dose interleukin-2 (IL-2) have consistently found clinical response rates of 50% or more in metastatic melanoma patients accompanied by long progression-free survival. Recent studies have also established practical methods for the expansion of TIL from melanoma tumors with high success rates. These results have set the stage for randomized phase II/III clinical trials to determine whether ACT provides benefit in stage IV melanoma. Here, we provide an overview of the current state-of-the art in T-cell-based therapies for melanoma focusing on ACT using expanded TIL and address some of the key unanswered biological and clinical questions in the field. Different phase II/III randomized clinical trial scenarios comparing the efficacy of TIL therapy to high-dose IL-2 alone are described. Finally, we provide a roadmap describing the critical steps required to test TIL therapy in a randomized multicenter setting. We suggest an approach using centralized cell expansion facilities that will receive specimens and ship expanded TIL infusion products to participating centers to ensure maximal yield and product consistency. If successful, this approach will definitively answer the question of whether ACT can enter mainstream treatment for cancer.
Similar articles
- TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S, Etto T, Rodríguez-Cruz T, Li Y, Wu C, Fulbright OJ, Hwu P, Radvanyi L, Lizée G. Liu S, et al. J Immunother. 2010 May;33(4):371-81. doi: 10.1097/CJI.0b013e3181cd1180. J Immunother. 2010. PMID: 20386469 - Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Besser MJ, et al. Clin Cancer Res. 2010 May 1;16(9):2646-55. doi: 10.1158/1078-0432.CCR-10-0041. Epub 2010 Apr 20. Clin Cancer Res. 2010. PMID: 20406835 Clinical Trial. - MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. Li Y, et al. J Immunol. 2010 Jan 1;184(1):452-65. doi: 10.4049/jimmunol.0901101. Epub 2009 Nov 30. J Immunol. 2010. PMID: 19949105 - Adoptive T-cell transfer in melanoma.
Itzhaki O, Levy D, Zikich D, Treves AJ, Markel G, Schachter J, Besser MJ. Itzhaki O, et al. Immunotherapy. 2013 Jan;5(1):79-90. doi: 10.2217/imt.12.143. Immunotherapy. 2013. PMID: 23256800 Review. - Tumor-infiltrating lymphocytes in melanoma.
Lee S, Margolin K. Lee S, et al. Curr Oncol Rep. 2012 Oct;14(5):468-74. doi: 10.1007/s11912-012-0257-5. Curr Oncol Rep. 2012. PMID: 22878966 Free PMC article. Review.
Cited by
- Extranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cells.
Chen L, Taylor JL, Sabins NC, Lowe DB, Qu Y, You Z, Storkus WJ. Chen L, et al. Cancer Gene Ther. 2013 Aug;20(8):469-77. doi: 10.1038/cgt.2013.42. Epub 2013 Jul 12. Cancer Gene Ther. 2013. PMID: 23846252 Free PMC article. - Notch signaling regulates antigen sensitivity of naive CD4+ T cells by tuning co-stimulation.
Laky K, Evans S, Perez-Diez A, Fowlkes BJ. Laky K, et al. Immunity. 2015 Jan 20;42(1):80-94. doi: 10.1016/j.immuni.2014.12.027. Epub 2015 Jan 1. Immunity. 2015. PMID: 25607460 Free PMC article. - Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.
Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI. Ramakrishnan R, et al. Cancer Res. 2012 Nov 1;72(21):5483-93. doi: 10.1158/0008-5472.CAN-12-2236. Epub 2012 Aug 31. Cancer Res. 2012. PMID: 22942258 Free PMC article. - Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
Niyongere S, Saltos A, Gray JE. Niyongere S, et al. J Thorac Dis. 2018 Feb;10(Suppl 3):S433-S450. doi: 10.21037/jtd.2017.12.120. J Thorac Dis. 2018. PMID: 29593889 Free PMC article. Review. - Genetically modified T cells in cancer therapy: opportunities and challenges.
Sharpe M, Mount N. Sharpe M, et al. Dis Model Mech. 2015 Apr;8(4):337-50. doi: 10.1242/dmm.018036. Epub 2015 Apr 1. Dis Model Mech. 2015. PMID: 26035842 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical